The disposition, metabolism, and pharmacokinetics of a selective metabotropic glutamate receptor agonist in rats and dogs

Drug Metabolism and Disposition

Volumn 30, Issue 1, 2002, Pages 27-33

  Johnson, J T ^a   Mattiuz, E L ^a   Chay, S H ^a   Herman, J L ^a   Wheeler, W J ^a   Kassahun, K ^a   Swanson, S P ^a   Phillips, D L ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EGLUMETAD; METABOTROPIC RECEPTOR AGONIST;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EXCRETION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG STRUCTURE; FEMALE; FOOD DRUG INTERACTION; GAS CHROMATOGRAPHY; GASTROINTESTINAL TRACT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; LIVER MICROSOME; MALE; MASS SPECTROMETRY; MEAN RESIDENCE TIME; NONHUMAN; PRIORITY JOURNAL; RAT; WHOLE BODY AUTORADIOGRAPHY;

ADMINISTRATION, ORAL; ANIMALS; ANTI-ANXIETY AGENTS; BICYCLO COMPOUNDS; BIOLOGICAL AVAILABILITY; BLOOD PROTEINS; DOGS; DRUG EVALUATION, PRECLINICAL; ERYTHROCYTES; EXCITATORY AMINO ACID AGONISTS; FEMALE; HUMANS; MALE; PROTEIN BINDING; RATS; RATS, INBRED F344; RECEPTORS, METABOTROPIC GLUTAMATE; TISSUE DISTRIBUTION;

ANIMALIA; CANIS FAMILIARIS;

EID: 0036136925     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.1.27     Document Type: Article

References (27)

1. Dose escalation study of the NMDA glycine-site antagonist licostinel in acute ischemic stroke
2. In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats
3. A novel orally active group 2 metabotropic glutamate receptor agonist: LY354740
4. Neuroprotective effects of a systemically active group II metabotropic glutamate receptor agonist LY354740 in a gerbil model of global ischaemia
5. An open-label study of CP-101.606 in subjects with a severe traumatic head injury or spontaneous intracerebral hemorrhage
6. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus D-amphetamine motor behaviors in rats
7. 14C]daptomycin in rats
8. Glutamate in CNS disorders
9. 2-Amino-3-(methylamino)-propanoic acid (BMAA) pharmacokinetics and blood-brain barrier permeability in the rat
10. Physiologically based pharmacokinetic modeling: Principles and applications
11. A role for metabotropic glutamate receptors in drug withdrawal states
12. Anxiolytic and side-effect profile of LY354740: A potent, highly selective, orally active agonist for group II metabotropic glutamate receptors
13. Renal function in man, dog and rat
14. Autoradiography using storage phosphor technology
15. Effects of the selective metabotropic glutamate agonist LY354740 in a rat model of permanent ischaemia
16. Metabolic, hormonal, and hemodynamic changes induced by metabotropic excitatory amino acid agonist (1S,3R)-ACPD
17. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740): A potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties
18. Molecular diversity of glutamate receptors and implications for brain function
19. Molecular diversity and functions of glutamate receptors
20. The metabotropic glutamate receptors: Structure and functions
21. Pharmacological characterization of metabotropic glutamate receptors linked to the inhibition of adenylate cyclase activity in rat striatal slices
22. 3H]LY354740, in rat brain
23. LY354740 is a potent and highly selective group II metabotropic glutamate receptor agonist in cells expressing human glutamate receptors
24. Potent, stereoselective, and brain region selective modulation of second messengers in the rat brain by (+)LY354740, a novel group II metabotropic glutamate receptor agonist
25. The technique of whole body autoradiography: Cryosectioning of large specimens
26. The selective mGlu2/3 receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal